Charles R Esther

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6262736/publications.pdf

Version: 2024-02-01

72 papers	3,165 citations	236925 25 h-index	161849 54 g-index
75 all docs	75 docs citations	75 times ranked	4147 citing authors

#	Article	IF	Citations
1	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016, 354, 751-757.	12.6	462
2	Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 117-123.	0.7	344
3	Potentiator ivacaftor abrogates pharmacological correction of Î”F508 CFTR in cystic fibrosis. Science Translational Medicine, 2014, 6, 246ra96.	12.4	279
4	Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children. PLoS Pathogens, 2018, 14, e1006798.	4.7	147
5	Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis. Science Translational Medicine, 2019, 11, .	12.4	146
6	Chronic E-Cigarette Use Increases Neutrophil Elastase and Matrix Metalloprotease Levels in the Lung. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1392-1401.	5.6	142
7	Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients. Biomarkers, 2009, 14, 55-60.	1.9	110
8	Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatric Pulmonology, 2005, 40, 39-44.	2.0	102
9	Lung transplant outcomes in cystic fibrosis patients with preâ€operative <scp>M</scp>ycobacterium abscessus respiratory infections. Clinical Transplantation, 2013, 27, 523-529.	1.6	97
10	Pulmonary lymphangiectasia: Diagnosis and clinical course. Pediatric Pulmonology, 2004, 38, 308-313.	2.0	78
11	An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 171-180.	5.6	77
12	Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L987-L993.	2.9	73
13	Atopic asthmatic subjects but not atopic subjects without asthma have enhanced inflammatory response to ozone. Journal of Allergy and Clinical Immunology, 2010, 126, 537-544.e1.	2.9	64
14	Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome. Journal of Experimental Medicine, 2020, 217, .	8.5	64
15	Endoplasmic Reticulum/Golgi Nucleotide Sugar Transporters Contribute to the Cellular Release of UDP-sugar Signaling Molecules. Journal of Biological Chemistry, 2009, 284, 12572-12583.	3.4	63
16	Metabolomic Evaluation of Neutrophilic Airway Inflammation in Cystic Fibrosis. Chest, 2015, 148, 507-515.	0.8	63
17	Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis. European Respiratory Journal, 2016, 48, 1612-1621.	6.7	63
18	Elevated Airway Purines in COPD. Chest, 2011, 140, 954-960.	0.8	58

#	Article	IF	Citations
19	Respiratory viruses are associated with common respiratory pathogens in cystic fibrosis. Pediatric Pulmonology, 2014, 49, 926-931.	2.0	45
20	Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. Journal of Cystic Fibrosis, 2018, 17, 779-782.	0.7	45
21	A mass spectrometric method to simultaneously measure a biomarker and dilution marker in exhaled breath condensate. Rapid Communications in Mass Spectrometry, 2008, 22, 701-705.	1.5	41
22	Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation. Expert Review of Precision Medicine and Drug Development, 2016, 1, 235-243.	0.7	34
23	Tracheostomy in children: Epidemiology and clinical outcomes. Pediatric Pulmonology, 2018, 53, 1269-1275.	2.0	32
24	Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 427-439.	5.6	31
25	Detection of Rapidly Growing Mycobacteria in Routine Cultures of Samples from Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2011, 49, 1421-1425.	3.9	29
26	Neutrophilic inflammation is associated with altered airway hydration in stable asthmatics. Respiratory Medicine, 2010, 104, 29-33.	2.9	26
27	Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor. Journal of Cystic Fibrosis, 2022, 21, 725-727.	0.7	26
28	Exhaled breath condensate adenosine tracks lung function changes in cystic fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 304, L504-L509.	2.9	22
29	Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients. Journal of Cystic Fibrosis, 2017, 16, 483-487.	0.7	22
30	Similarities between UDP-Glucose and Adenine Nucleotide Release in Yeast: Involvement of the Secretory Pathwayâ€. Biochemistry, 2008, 47, 9269-9278.	2.5	21
31	Sialic acid-to-urea ratio as a measure of airway surface hydration. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L398-L404.	2.9	21
32	Airway Epithelial Inflammation In Vitro Augments the Rescue of Mutant CFTR by Current CFTR Modulator Therapies. Frontiers in Pharmacology, 2021, 12, 628722.	3.5	20
33	Phenotypes of CF rabbits generated by CRISPR/Cas9-mediated disruption of the CFTR gene. JCI Insight, 2021, 6, .	5.0	20
34	Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD. Chest, 2022, 161, 1239-1249.	0.8	20
35	Airway purinergic responses in healthy, atopic nonasthmatic, and atopic asthmatic subjects exposed to ozone. Inhalation Toxicology, 2011, 23, 324-330.	1.6	19
36	Exhaled breath condensate purines correlate with lung function in infants and preschoolers. Pediatric Pulmonology, 2013, 48, 182-187.	2.0	19

#	Article	IF	Citations
37	Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy. Journal of Cystic Fibrosis, 2020, 19, 742-745.	0.7	16
38	Nucleotide Release by Airway Epithelia. Sub-Cellular Biochemistry, 2011, 55, 1-15.	2.4	15
39	Airway drug pharmacokinetics via analysis of exhaled breath condensate. Pulmonary Pharmacology and Therapeutics, 2014, 27, 76-82.	2.6	13
40	Transition and post-transition metals in exhaled breath condensate. Journal of Breath Research, 2018, 12, 027112.	3.0	12
41	Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection. Journal of Cystic Fibrosis, 2016, 15, e45-e49.	0.7	11
42	Impact of an evidenceâ€based algorithm on quality of care in pediatric parapneumonic effusion and empyema. Pediatric Pulmonology, 2011, 46, 722-728.	2.0	10
43	Lung disease phenotypes caused by over-expression of combinations of alpha, beta, and gamma subunits of the epithelial sodium channel in mouse airways. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, ajplung.00382.2.	2.9	10
44	Highlights from the 2016 North American Cystic Fibrosis Conference. Pediatric Pulmonology, 2017, 52, 1103-1110.	2.0	10
45	Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers. Pediatric Pulmonology, 2017, 52, S21-S28.	2.0	10
46	Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series. Journal of Cystic Fibrosis, 2019, 18, e42-e44.	0.7	10
47	Novel end points for clinical trials in young children with cystic fibrosis. Expert Review of Respiratory Medicine, 2013, 7, 231-243.	2.5	9
48	Loss of Î² Epithelial Sodium Channel Function in Meibomian Glands Produces Pseudohypoaldosteronism 1â€“Like Ocular Disease in Mice. American Journal of Pathology, 2018, 188, 95-110.	3.8	9
49	Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment. Journal of Cystic Fibrosis, 2020, 19, 746-751.	0.7	9
50	Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis. Pediatric Pulmonology, 2020, 55, 521-525.	2.0	8
51	Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study. BMC Pediatrics, 2020, 20, 559.	1.7	8
52	Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 959-966.	0.7	8
53	Highlights from the 2017 North American Cystic Fibrosis Conference. Pediatric Pulmonology, 2018, 53, 979-986.	2.0	7
54	Regulation of Airway Nucleotides in Chronic Lung Diseases. Sub-Cellular Biochemistry, 2011, 55, 75-93.	2.4	7

#	Article	IF	Citations
55	Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series. Journal of Cystic Fibrosis, 2018, 17, e48-e50.	0.7	6
56	Regional Differences in Mucociliary Clearance in the Upper and Lower Airways. Frontiers in Physiology, 2022, 13, 842592.	2.8	5
57	Diagnostic Evaluation of Infants with Recurrent or Persistent Wheezing. Annals of the American Thoracic Society, 2016, 13, 2057-2059.	3.2	4
58	Continuous vancomycin in a pediatric cystic fibrosis patient. Pediatric Pulmonology, 2018, 53, E4-E5.	2.0	4
59	The future of pediatric pulmonology: A survey of division directors, assessment of current research funding, and discussion of workforce trends. Pediatric Pulmonology, 2023, 58, 653-661.	2.0	4
60	Effects of repleting organic phosphates in banked erythrocytes on plasma metabolites and vasoactive mediators after red cell exchange transfusion in sickle cell disease. Blood Transfusion, 2020, 18, 200-207.	0.4	4
61	Positional impairment of gas exchange during diaphragm pacing alleviated by increasing amplitude settings in congenital central hypoventilation syndrome. Journal of Clinical Sleep Medicine, 2020, 16, 459-462.	2.6	4
62	Pharmacokineticâ€based failure of a detergent virucidal for severe acute respiratory syndromeâ€“coronavirusâ€2 (SARSâ€CoVâ€2) nasal infections: A preclinical study and randomized controlled trial. International Forum of Allergy and Rhinology, 2022, , .	2.8	4
63	Detection of Mycobacterium abscessus from Deep Pharyngeal Swabs in Cystic Fibrosis. Infection Control and Hospital Epidemiology, 2015, 36, 618-619.	1.8	3
64	Novel therapies for treatment of resistant and refractory nontuberculous mycobacterial infections in patients with cystic fibrosis. Pediatric Pulmonology, 2021, 56, S55-S68.	2.0	3
65	An assessment of fellowship training issues affecting the pediatric pulmonary medicine workforce. Pediatric Pulmonology, 2023, 58, 665-669.	2.0	3
66	Highlights from the 2019 North American Cystic Fibrosis Conference. Pediatric Pulmonology, 2020, 55, 2225-2232.	2.0	2
67	Inverse probability weighted estimation for recurrent events data with missing category. Statistics in Medicine, 2021, 40, 2765-2782.	1.6	2
68	Semiparametric estimation of the proportional rates model for recurrent events data with missing event category. Statistical Methods in Medical Research, 2021, 30, 1624-1639.	1.5	2
69	Metabolomics of airways disease in cystic fibrosis. Current Opinion in Pharmacology, 2022, 65, 102238.	3.5	2
70	Metabolomic profiling of extraesophageal reflux disease in children. Clinical and Translational Science, 2021, 14, 2025-2033.	3.1	1
71	American Thoracic Society 2019 Pediatric Core Curriculum. Pediatric Pulmonology, 2019, 54, 1880-1894.	2.0	0
72	Community health worker caseâ€detection of asthma or reactive airways disease in a resourceâ€poor community in Nicaragua. Pediatric Pulmonology, 2021, 56, 1145-1154.	2.0	0